



Spring Group Meeting

San Francisco Specials

APRIL 30 - MAY 2, 2026



Symptom Management &
Survivorship Committee

Symptom Management & Survivorship Committee

Leadership

Co-Chairs: Michael J. Fisch, MD, MPH
 Norah Lynn Henry, MD, PhD

Time/Location

Thursday, April 30, 2026 2:00 p.m. - 4:00 p.m.
 Room: Bayview Room (Bay Level)

Agenda

Welcome & Introductions: Drs. Fisch and Henry

Patient Advocate Update: Lee Jones

Research Update:

A Comparison of Minimally Important Difference Definitions for Quality of Life in Four Clinical Trials (presented at ISOQOL 2025): Dr. Salene Jones

Updates on Concepts in Development

Updates on Active Trials

Brainstorming Session - Future Directions of the SMS Committee: Fostering Collaborations to Develop Concepts and Explore Secondary Analyses

Concepts in Development

S2435, "App-Supported Sleep Coaching for Cancer Survivors and Their Bedroom Partners." Study Chair: Dr. Rina S. Fox.

SXXXX, "RECOG: RELugolix vs. GnRH agonist: Evaluation of COGNitive outcomes in prostate cancer." Study Chairs: Drs. Clara Hwang and Laura Graham

SXXXX, "Vitamin D for Prevention of Taxane-Induced Peripheral Neuropathy." Study Chairs: Drs. Meghna Trivedi and Daniel Hertz.

Active Studies

S2013, "Immune Checkpoint Inhibitor Toxicity (I-CHECKIT): A Prospective Observational Study." Study Chairs: Drs. Krishna S. Gunturu and Dawn L. Hershman. Activated: 8/16/21.

S2205, "ICE COMPRESS: Randomized Trial of Limb Cryocompression Versus Continuous Compression Versus Low Cyclic Compression for the Prevention of Taxane-Induced Peripheral Neuropathy." Study Chairs: Drs. Melissa K. Accordino and Katheryn Pennington. Activated: 3/16/23.

Closed Studies

S1600, "A Randomized Phase III Double-Blind Clinical Trial Evaluating the Effect of Immune-Enhancing Nutrition on Radical Cystectomy Outcomes (SIMMune)." Study Chairs: Drs. Jill Hamilton-Reeves and Jeffrey M. Holzbeierlein. Activated: 2/21/19; Permanently closed: 10/20/23.

S1614, "A Phase III Randomized Trial of Prophylactic Antiviral Therapy in Patients with Current or Past Hepatitis B Virus (HBV) Infection Receiving Anti-Cancer Therapy for Solid Tumors." Drs. Jessica Hwang, Anna S. Lok, Adam Gehring, and Jordan Feld. Activation: 2/21/19; Permanently closed: 11/15/22.

S1714, "A Prospective Observational Cohort Study to Develop a Predictive Model of Taxane-Induced Peripheral Neuropathy in Cancer Patients." Study Chairs: Drs. Meghna S.Trivedi, Dawn L. Hershman, and Thomas H. Brannagan. Activated: 3/1/19; Permanently closed: 11/15/21.

S2010, "A Randomized Phase III Trial Comparing Active Symptom Monitoring Plus Patient Education Versus Patient Education Alone to Improve Persistence with Endocrine Therapy in Young Women with Stage I-III Breast Cancer (ASPEN)." Study Chairs: Drs. N. Lynn Henry and Dawn L. Hershman. Activated: 1/17/23; Permanently closed: 1/15/25.

Other SWOG Studies with Symptom Management and Survivorship Component

Breast

S1706, "A Phase II Randomized, Double-Blinded, Placebo-Controlled Trial of Olaparib Administered Concurrently with Radiotherapy for Inflammatory Breast Cancer." Study Chairs: Drs. Reshma Jags, Pavani Chalasani, Jean Moran, and Corey Speers. Activated: 9/12/18; Permanently closed: 7/1/24.

Cancer Care Delivery

S1703, "Randomized Non-Inferiority Trial Comparing Overall Survival of Patients Monitored with Serum Tumor Marker Directed Disease Monitoring (Stmddm) Versus Usual Care in Patients with Metastatic Hormone Receptor Positive Her-2 Negative Breast Cancer." Study Chairs: Drs. Melissa K. Accordino, Dawn Hershman, and Scott D. Ramsey. Activated: 7/16/18.

S1904, "Cluster Randomized Controlled Trial of Patient and Provider Decision Support To Increase Chemoprevention Informed Choice Among Women with Atypical Hyperplasia or Lobular Carcinoma in Situ - Making Informed Choices on Incorporating Chemoprevention into Care

Symptom Management & Survivorship Committee

(MiCHOICE).” Study Chairs: Drs. Katherine D. Crew, Rita Kukafka, Dawn L. Hershman, Parijatham Thomas, and Allison Caban-Holt. Activated: 9/1/20; Permanently closed: 6/14/24.

S1912CD, “A Randomized Trial Addressing Cancer-Related Financial Hardship Through Delivery of a Proactive Financial Navigation Intervention (CREDIT).” Study Chairs: Drs. Veena Shankaran, Ruth Carlos, Dawn L. Hershman, Shelby Langer, and Scott D. Ramsey. Activated: 7/26/21; Permanently closed: 12/16/24.

S2108CD, “A Cluster Randomized Trial Comparing an Educationally Enhanced Genomic Tumor Board (EGTB) Intervention to Usual Practice to Increase Evidence-Based Genome-Informed Therapy.” Study Chairs: Drs. Jens Rueter, Meghna S. Trivedi, Banu E. Symington, Paul Tseng, and Dawn L. Hershman. Activated: 8/22/22; Permanently closed: 11/22/24.

GU

S1802, “Phase III Randomized Trial of Standard Systemic Therapy (SST) Versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer.” Study Chairs: Drs. Brian F. Chapin, Ana Aparicio, and Richard Valicent. Activated: 9/17/18.

S1806, “Phase III Randomized Trial of Concurrent Chemoradiotherapy with or Without Atezolizumab in Localized Muscle Invasive Bladder Cancer.” SWOG Study Chair: Drs. Parminder Singh, Seth P. Lerner, and Sameer Jhavar. Activated: 4/19/18; Permanently closed: 4/1/24.

GI

S0820, “A Double-Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon or Rectal Cancer, Phase III – Preventing Adenomas of the Colon with Eflornithine and Sulindac (PACES).” Study Chairs: Drs. Jason A. Zell, Lance, and Powel H. Brown. Activated: 3/1/13; Permanently closed: 6/30/23.

Leukemia

S1925, “Randomized, Phase III Study of Early Intervention with Venetoclax and Obinutuzumab Versus Delayed Therapy with Venetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): EVOLVE CLL/SLL Study.” Study Chairs: Drs. Deborah Stephens, Brian Hill, and Mazyar Shadman. Activated: 12/14/20.

Lung

S1914, “A Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC#783608) + SBRT Versus SBRT Alone in High Risk, Early Stage NSCLC.” Study Chairs: Drs. Megan E. Daly, Charles B. Simone, II, Karen Kelly, and Jeffrey D. Bradley. Activated: 3/25/20.

S1827, “MRI Brain Surveillance Alone Versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer (MAVERICK).” Study Chairs: Drs. Chad Rusthoven, Paul Brown, Jeffrey S. Wefel, Abhijit Patel, and N. Lynn Henry. Activated: 1/10/20; Permanently closed: 12/15/25.

Lymphoma

S1826, “A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age \geq 12 Years) with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma.” Study Chairs: Drs. Alex F. Herrera and Jonathan Friedberg. Activated: 7/19/19; Permanently closed: 12/1/22.

S1918, “A Phase II/III Randomized Study of R-miniCHOP with or without Oral Azacitidine (CC-486) in Participants Age 75 Years or Older with Newly Diagnosed Diffuse Large B Cell Lymphoma, Grade IIIb Follicular Lymphoma, Transformed Lymphoma, and High-Grade B-cell Lymphomas with MYC and BCL2 and/or BCL6 Rearrangements.” Study Chairs: Drs. Elizabeth Brem and Sonali Smith. Activated: 3/19/21; Temporarily closed: 4/1/25.

Myeloma

S1803, “Phase III Study of Daratumumab/rHuPH20 (NSC- 810307) + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients with Multiple Myeloma (MM) Using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC Study).” Study chairs: Drs. Amrita Krishnan, Saurabh Chhabra, and Natalie S. Callander. Activated: 6/27/19; Step 1 Closed to accrual: 1/15/25.

NCTN Studies

CTSU/NRG-G1004, “Colorectal Cancer Metastatic dMMR Immunotherapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab Combination Chemotherapy with or Without Atezolizumab or Atezolizumab Monotherapy in the First Line Treatment of Patients with Deficient DNA Mismatch Repair (dMMR) Metastatic Colorectal Cancer.” Dr. Caio Max Sao Pedro Rocha Lima and Michael Overman. Activated: 11/7/17; Temporarily closed: 6/4/20; Reactivated: 1/29/21; Permanently closed: 9/2/25.

Symptom Management & Survivorship Committee

Publications

The publication papers listed below from 2025 and 2026 have not appeared in previous Group Meeting publications listings. Accepted and submitted manuscripts are also listed, with the journal names withheld to honor journal embargo policies. Conference abstracts are not included.

Published/Accepted Manuscripts

S1007 Cognitive Impairment and Chemoendocrine vs Endocrine Therapy in Pre- and Postmenopausal Women: A Secondary Analysis of the RxPONDER Randomized Clinical Trial. Irene M Kang, Jamie K Forschmiedt, Michelle M Loch, Danika L Lew, William E Barlow, Julie R Gralow, Funda Meric-Bernstam, Kathy S Albain, Daniel F Hayes, Nancy U Lin, Edith A Perez, Lori J Goldstein, Priya Rastogi, Anne F Schott, Rick Baehner, Priyanka Sharma, Debasish Tripathy, Lajos Pusztai, Gabriel N Hortobagyi, Kevin Kalinsky, N Lynn Henry. *JAMA Oncol*. 2025 Dec 11:e255220. doi: 10.1001/jamaoncol.2025.5220. Online ahead of print. [see also Breast Committee] <https://pubmed.ncbi.nlm.nih.gov/41379459>

S1714 Risk Prediction Model for Taxane-Induced Peripheral Neuropathy in Early-Stage Cancer: SWOG S1714. M Trivedi, J Unger, NL Henry, A Darke, D Hertz, T Brannagan, S Reyes, B Schneider, W Irvin, A Hathaway, A Vander Woude, V Gudena, P Cabrera-Galeana, M Orsted, M LeBlanc, M Fisch, D Hershman. Accepted, 2026.

Multiple Studies Baseline Fatigue and Severe Toxic Effects in Patients With Cancer Receiving Systemic Therapy. Joseph M Unger, Michael J Fisch, Salene M W Jones, N Lynn Henry, Dawn L Hershman. *JAMA Oncol*. 2026;12(2):185-193. 10.1001/jamaoncol.2025.5549. Epub 2025 Dec 26. <https://pubmed.ncbi.nlm.nih.gov/41452615/>

A221405 Breastfeeding after hormone-receptor positive breast cancer: results from the POSITIVE trial. Fedro A Peccatori, Samuel M Niman, Ann H Partridge, Monica Ruggeri, Marco Colleoni, Cristina Saura, Chikako Shimizu, Anna B Satersdal, Judith R Kroep, Karen Gelmon, Frederic Amant, Audrey Mailliez, Halle C F Moore, Manuel Ruiz-Borrego, Janice M Walshe, Virginia F Borges, Andrea Gombos, Akemi Kataoka, Christine Rousset-Jablonski, Simona Borstnar, Junko Takei, Jeong E Lee, Christobel Saunders, Vesna Bjelic-Radisic, Snezana Susnjar, Fatima Cardoso, Natalie J Klar, Teresa Ferreiro, Sarra El-Abed, Martine Piccart, Larissa A Korde, Aron Goldhirsch, Richard D Gelber, Olivia Pagani, Hatem A Azim Jr; International Breast Cancer Study Group and the POSITIVE Trial Collaborators. *Journal of Clinical Oncology*, 2025 Aug 20;43(24):2712-2719. doi: 10.1200/JCO-24-02697. Epub 2025 Jul 9. [see also Breast Committee] <https://pubmed.ncbi.nlm.nih.gov/40632989/>

A221405 Hormonal factors predictive of fertility in patients with

breast cancer interrupting adjuvant endocrine therapy to attempt pregnancy in POSITIVE trial. Isabelle Demeestere, Samuel M Niman, Ann H Partridge, Daniela S Diego, Roswitha Kammler, Monica Ruggeri, Marco Colleoni, Chikako Shimizu, Cristina Saura, Karen A Gelmon, Anna B Saetersdal, Judith R Kroep, Audrey Mailliez, Frederic Amant, Manuel Ruiz-Borrego, Jeong Eon Lee, Akemi Kataoka, Janice M Walshe, Junko Takei, Simona Borstnar, Virginia F Borges, Christobel Saunders, Snezana Susnjar, Vesna Bjelic-Radisic, Fatima Cardoso, Jane Lowe Meisel, Jennifer F Kawwass, Tanja Spanic, Sarra El-Abed, Martine Piccart, Larissa A Korde, Aron Goldhirsch, Richard D Gelber, Olivia Pagani, Hatem A Azim Jr, Fedro A Peccatori; International Breast Cancer Study Group and the POSITIVE Trial Collaborators. *Breast*. 2025 Oct;83:104547. doi: 10.1016/j.breast.2025.104547. Epub 2025 Jul 26.

<https://pubmed.ncbi.nlm.nih.gov/40743662/>

Submitted Manuscripts

S1600 Effects of Immune-Enhancing Nutrition on Outcomes after Radical Cystectomy: Primary Results from a Randomized Phase III Double-Blind Clinical Trial (SWOG S1600). Jill M. Hamilton-Reeves, Joseph M. Unger, Jeffrey M. Holzbeierlein, Danika L. Lew, J. Ryan Mark, Siamak Daneshmand, Seth P. Lerner, Janet E.B. Kukreja, Eugene K. Lee, William B. Tabayoyong, Dawn L. Hershman, Michael J. Fisch, N. Lynn Henry. Submitted 2026.

S1600 Flow Cytometry Method To Identify Arginase-1 Expressing MDSCs. Pugazhendhi Srinivasan, Misty Bechtel, Dorota Wyczechowska, Augusto Ochoa, Michael J. Fisch, N. Lynn Henry, Joseph M. Unger, Jill M. Hamilton-Reeves. Submitted 2026.

S1706 Toxicity in a Randomized Trial Comparing Radiotherapy +/- Olaparib for Inflammatory Breast Cancer. Reshma Jaggi, Allison Meisner, Pavani Chalasani, William E. Barlow, Jennifer R. Bellon, Norah N. Lynn Henry, Danika Lew, Martha M. Matuszak, Jean M. Moran, Lori J. Pierce, Eileen Rakovitch, Stephanie J. Reyes, Corey Speers, Joseph M. Unger, Julia R. White, Wendy A. Woodward, Richard Cedric Zellars, Lajos Pusztai, Priyanka Sharma. Submitted 2025. [see also Breast Committee]

NRG-GI004/S1610 Randomized Phase III Study of mFOLFOX/ Bevacizumab/Atezolizumab or Atezolizumab alone as First-line Treatment of Deficient DNA-Mismatch Repair Metastatic Colorectal Cancer. Caio Max Sao Pedro Rocha Lima, Greg Yothers, Thomas J. George, Howard S. Hochster, Hanna K. Sanoff, Deirdre J. Cohen, Katherine A. Guthrie, Samuel A. Jacobs, Anwaar Saeed, Scott Kopetz, Linda H. Colangelo, Tanner J. Freeman, Scott W. Cole, Maged Khalil, Swapna Devanna, Dan S. Zuckerman, Theodore S. Hong, N. Lynn Henry, Patricia A. Ganz, Charles D. Blanke, Norman Wolmark, Michael J. Overman. Submitted 2026. [see also Gastrointestinal Committee]

Symptom Management & Survivorship Committee

Accrual from trials that are open as of 12/31/2025 or have closed in the prior 18 Months by Institution and Study

	S2010	S2013	S2205	A211901	A222004	ACCL1931	EAQ202	EAQ211
Audie L Murphy VA Hospital	-	26	-	-	-	-	-	-
Banner University Medical Center - Tucson	-	5	-	-	-	-	-	-
Baptist Memorial Health Care/Mid South Minority Underserved NCORP	-	-	-	-	-	-	-	-
Cancer Research Consortium of West Michigan NCORP	2	-	1	-	-	-	-	-
Cancer Research for the Ozarks NCORP	-	12	-	-	-	-	-	-
Cancer Research of Wisconsin and Northern Michigan Consortium	4	168	-	-	-	-	-	-
Carle Cancer Center NCI Community Oncology Research Program	1	19	-	-	-	-	-	-
Columbia University Minority Underserved NCORP	26	45	38	-	1	-	-	-
Columbus NCI Community Oncology Research Program	-	37	-	-	-	-	-	-
CommonSpirit Health Research Institute	13	-	-	-	-	-	-	-
Dayton NCI Community Oncology Research Program	-	-	-	-	-	-	-	-
Essentia Health NCI Community Oncology Research Program	-	-	-	-	-	-	-	1
Georgia Cares Minority Underserved NCORP	-	35	-	-	-	-	-	-
Georgia NCI Community Oncology Research Program	20	74	-	2	-	-	-	-
Grupo Oncologico Cooperativo de Investigacion	-	9	-	-	-	-	-	-
Gulf South Minority Underserved NCORP	4	-	-	-	-	-	-	-
Hawaii Minority Underserved NCORP	9	9	43	-	-	-	-	-
Heartland Cancer Research NCORP	25	268	-	-	-	-	-	-
Henry Ford Hospital	-	29	4	-	-	-	-	-
Instituto Nacional De Cancerologia de Mexico	27	13	-	-	-	-	-	-
Instituto Nacional de Enfermedades Neoplasticas	24	-	-	-	-	-	-	-
Intermountain Medical Center	-	3	-	-	-	-	-	-
Kaiser Permanente NCI Community Oncology Research Program	28	85	-	-	-	-	-	-
Lahey Hospital and Medical Center	12	63	-	-	-	-	-	-
Massachusetts Veterans Epidemiology Research and Information Center	-	63	-	-	-	-	-	-
Mercy Medical Center - Des Moines	-	9	-	-	-	-	-	-
Michigan Cancer Research Consortium NCORP	20	14	-	-	-	-	-	-
Moffitt Cancer Center	10	-	-	-	-	-	-	-
Montana Cancer Consortium NCORP	-	7	-	-	-	-	-	-
Mount Sinai Hospital	-	-	-	-	-	-	-	-
NCORP of the Carolinas (Prisma Health NCORP)	-	-	-	-	-	-	39	-
Nevada Cancer Research Foundation NCORP	-	-	-	-	3	-	4	-
New Mexico Minority Underserved NCORP	21	-	26	-	-	-	-	-
Northwestern University LAPS	7	-	-	-	-	-	-	-

Symptom Management & Survivorship Committee

Accrual from trials that are open as of 12/31/2025 or have closed in the prior 18 Months by Institution and Study

	S2010	S2013	S2205	A211901	A222004	ACCL1931	EAQ202	EAQ211
Oregon Health and Science University	-	12	-	-	-	1	-	-
Our Lady of the Lake Hospital	-	25	-	-	-	-	-	-
Pacific Cancer Research Consortium NCORP	11	3	-	-	-	-	-	-
Regents of the University of Michigan	31	-	-	-	-	-	-	-
Rhode Island Hospital	-	-	17	-	-	-	-	-
STCC at DHR Health Institute for Research and Development	18	55	21	7	-	-	-	-
Salem Hospital	-	-	-	-	-	-	-	-
Southeast Clinical Oncology Research Consortium NCORP	2	185	87	-	-	-	-	-
Stanford Cancer Institute Palo Alto	-	-	-	-	-	5	-	4
The Don and Sybil Harrington Cancer Center	10	4	-	-	1	-	-	-
Tufts Medical Center	-	-	-	-	-	-	1	-
UC Davis Comprehensive Cancer Center LAPS	7	13	-	-	-	-	-	-
UC Irvine Health/Chao Family Comprehensive Cancer Center	-	6	-	-	-	-	-	-
UC San Diego Moores Cancer Center	2	2	-	-	-	-	-	-
UPMC Hillman Cancer Center LAPS	5	-	-	-	-	-	-	-
USC Norris Comprehensive Cancer Center LAPS	-	12	-	-	-	-	-	-
Universidad de la Republica - Facultad de Medicina	4	22	-	-	-	-	-	-
U of Alabama at Birmingham / Deep South Research Consortium LAPS	-	-	6	-	-	-	-	-
University of Arkansas for Medical Sciences	6	25	-	-	-	-	-	-
University of Colorado Cancer Center LAPS	3	38	-	-	-	-	-	-
University of Kansas Cancer Center - MCA Rural MU NCORP	18	88	22	1	-	2	-	2
University of Kentucky/Markey Cancer Center	-	-	-	-	-	-	-	-
University of Mississippi Medical Center	1	-	-	-	-	-	-	-
University of Oklahoma Health Sciences Center LAPS	2	-	-	-	-	-	-	-
University of Rochester LAPS	-	-	-	-	-	-	-	12
University of Texas Health Science Center at San Antonio	17	53	-	-	-	-	-	-
University of Utah - Huntsman Cancer Institute LAPS	1	3	-	6	2	-	-	-
Upstate Carolina Consortium Community Oncology Research Program	-	-	23	-	-	-	-	-
Western States Cancer Research NCORP	-	1	4	-	-	-	-	-
Wisconsin NCI Community Oncology Research Program	8	33	-	-	-	-	-	-
Yale University - Yale Cancer Center LAPS	-	-	3	-	-	-	-	-
ALLIANCE	42	372	76	-	-	-	-	-
ECOG-ACRIN	37	125	13	-	-	-	-	-
NRG	87	291	139	-	-	-	-	-
Total	565	2,361	523	16	7	8	44	19

Symptom Management & Survivorship Committee

Accrual from trials that are open as of 12/31/2025 or have closed in the prior 18 Months by Institution and Study

	NRGCC010	NRGCC011
Audie L Murphy VA Hospital	-	-
Banner University Medical Center - Tucson	-	-
Baptist Memorial Health Care/Mid South Minority Underserved NCORP	-	2
Cancer Research Consortium of West Michigan NCORP	-	-
Cancer Research for the Ozarks NCORP	-	-
Cancer Research of Wisconsin and Northern Michigan Consortium	-	-
Carle Cancer Center NCI Community Oncology Research Program	-	-
Columbia University Minority Underserved NCORP	-	-
Columbus NCI Community Oncology Research Program	-	-
CommonSpirit Health Research Institute	-	-
Dayton NCI Community Oncology Research Program	-	1
Essentia Health NCI Community Oncology Research Program	-	-
Georgia Cares Minority Underserved NCORP	-	-
Georgia NCI Community Oncology Research Program	-	-
Grupo Oncologico Cooperativo de Investigacion	-	-
Gulf South Minority Underserved NCORP	13	-
Hawaii Minority Underserved NCORP	-	-
Heartland Cancer Research NCORP	-	-
Henry Ford Hospital	-	-
Instituto Nacional De Cancerologia de Mexico	-	-
Instituto Nacional de Enfermedades Neoplasicas	-	-
Intermountain Medical Center	-	-
Kaiser Permanente NCI Community Oncology Research Program	-	-
Lahey Hospital and Medical Center	-	4
Massachusetts Veterans Epidemiology Research and Information Center	-	-
Mercy Medical Center - Des Moines	-	-
Michigan Cancer Research Consortium NCORP	-	-
Moffitt Cancer Center	-	-
Montana Cancer Consortium NCORP	-	-
Mount Sinai Hospital	-	2
NCORP of the Carolinas (Prisma Health NCORP)	-	-
Nevada Cancer Research Foundation NCORP	-	-
New Mexico Minority Underserved NCORP	-	-
Northwestern University LAPS	-	-

Symptom Management & Survivorship Committee

Accrual from trials that are open as of 12/31/2025 or have closed in the prior 18 Months by Institution and Study

	NRGCC010	NRGCC011
Oregon Health and Science University	-	-
Our Lady of the Lake Hospital	-	-
Pacific Cancer Research Consortium NCORP	-	-
Regents of the University of Michigan	-	-
Rhode Island Hospital	-	-
STCC at DHR Health Institute for Research and Development	-	-
Salem Hospital	-	12
Southeast Clinical Oncology Research Consortium NCORP	-	-
Stanford Cancer Institute Palo Alto	-	-
The Don and Sybil Harrington Cancer Center	-	-
Tufts Medical Center	-	-
UC Davis Comprehensive Cancer Center LAPS	-	2
UC Irvine Health/Chao Family Comprehensive Cancer Center	-	-
UC San Diego Moores Cancer Center	-	-
UPMC Hillman Cancer Center LAPS	-	-
USC Norris Comprehensive Cancer Center LAPS	-	-
Universidad de la Republica - Facultad de Medicina	-	-
U of Alabama at Birmingham / Deep South Research Consortium LAPS	-	-
University of Arkansas for Medical Sciences	-	-
University of Colorado Cancer Center LAPS	-	-
University of Kansas Cancer Center - MCA Rural MU NCORP	-	12
University of Kentucky/Markey Cancer Center	-	3
University of Mississippi Medical Center	-	-
University of Oklahoma Health Sciences Center LAPS	2	-
University of Rochester LAPS	-	-
University of Texas Health Science Center at San Antonio	-	-
University of Utah - Huntsman Cancer Institute LAPS	-	-
Upstate Carolina Consortium Community Oncology Research Program	-	-
Western States Cancer Research NCORP	-	-
Wisconsin NCI Community Oncology Research Program	-	-
Yale University - Yale Cancer Center LAPS	-	-
ALLIANCE	-	-
ECOG-ACRIN	-	-
NRG	-	-
Total	15	38

